High-sensitivity C-Reactive Protein concentration in Patients with Acute Coronary Syndrome of Central India

Authors
Dr Mayank Jain¹, Dr Priyanka Kiyawat²

¹Consultant Interventional Cardiologist, Choithram Hospital and Research Centre (CHRC), Indore
²Asst. Prof., Dept. of Pathology, Sri Aurobindo Medical College and PG Institute, Indore (M.P.)

Abstract

Background and Objectives: Atherosclerosis is now known to be an active process of cell activation, inflammation and thrombosis.¹ To study, the serum hs-CRP level, a biomarker of inflammation in patients with acute coronary syndrome, such studies are sparse in India.

Methods: Patients with ACS who were fulfilling the inclusion criteria, attending cardiology services of Choithram Hospital and Research Centre (CHRC), Indore (a teaching hospital), were enrolled prospectively in the study during the period February 2017 to February 2018. The patients were further classified three risk groups according to serum hs-CRP levels. < 1 mg/L - low risk, 1-3 mg/L - average risk and >3 mg/L - high risk.

Results: In our study, majority of the patients were having serum hs-CRP level >3 mg/L putting them in high risk category. Of 100 patients, 60 patients (60%) had serum hs-CRP level > 3mg/l, 33 patients (33%) were having serum hs-CRP level 1-3mg/l, while only 7 patients (7%) had serum hs-CRP level < 1. The mean value of the serum hs-CRP levels in our study were 4.18±3.30 mg/L. In patients with unstable angina serum hs-CRP was 2.43±1.67 mg/l, with NSTEMI it was 3.70±2.09 mg/l and with STEMI it was highest 5.41±3.83 mg/l.

Conclusion: In our study we showed, the mean value of the serum hs-CRP levels in Indian subjects were 4.18±3.30 mg/L, which is higher to those reported in other ethnic groups.

Introduction
Atherosclerosis, once considered to result from a passive process of lipid accumulation, is now known to be an active process of cell activation, inflammation and thrombosis.¹ Over the past decade, identification of novel risk factors and predictors for CVD has been an area of major interest in preventive cardiology. Serum high sensitivity C-reactive protein (hs-CRP), a biomarker of inflammation, has been shown to effectively predict the risk of adverse cardiovascular (CV) events consistently. Serum hs-CRP levels may aid in identifying patients at high risk for a first CV event who might otherwise be missed by screening for lipids and other conventional risk factors alone. Studies discussing serum hs-CRP in patients with
Acute coronary syndrome are available in Western literature, such similar studies are however sparse in India. The need for such a study assumes tremendous significance as it is well known that the patient population and pattern of disease in India varies considerably from that of the West.

**Aims and Objectives**
To study the serum hs-CRP level in patients with acute coronary syndrome.

**Material and Methods**
During the period February 2017 to February 2018, total 100 patients with the clinical diagnosis of acute coronary syndrome, who were fulfill the following criteria, included in the study. The definition of ACS was made according to the 2012 “Third universal definition of myocardial infarction” expert consensus document.

**Inclusion Criteria**
- Patients with acute coronary syndrome irrespective of risk factors.
- Patient/party willing to give informed consent for active participation in the study.

**Exclusion Criteria**
- Patients on statins for more than one month,
- Patients with any systemic infection,
- Patients with malignancies,
- Patients with rheumatologic/autoimmune diseases,
- Patients with chronic inflammatory disorders,
- Patients with renal/hepatic compromise,
- Patients with recent trauma.
- Patients' refusal to give consent.
- Patients with psychiatric illness and those under legal custody.

It was a hospital based non-comparative prospective cross-sectional study. Serum hs-CRP assessment was performed using the IMMULITE method containing one monoclonal and one polyclonal anti-CRP antibodies. This method provides a measurement range from 0.1 to 500 mg/L.

Patients were divided into three risk groups according to serum hs-CRP levels.
- < 1 mg/L - low risk,
- 1-3 mg/L - average risk
- >3 mg/L - high risk.

**Observations**

**Baseline Characteristics**
Table No. 1 shows the baseline characteristics of study participants.

| Characteristic | Value |
|----------------|-------|
| Age (Years) (mean± SD, range) | 56.61±10.0 (29-86) |
| Sex | No. (%) |
| Male | 77 (77%) |
| Female | 23 (23%) |
| Type of Presentation | |
| STEMI | 52 (52%) |
| NSTEMI | 16 (16%) |
| UA | 32 (32%) |
| Serum hs-CRP Level | |
| < 1 mg/L - low risk | 7 (7%) |
| 1-3 mg/L - average risk | 33 (33%) |
| >3 mg/L - high risk | 60 (60%) |
| Risk Factor | |
| Smoking | 69 (69%) |
| Hypertension | 47 (47%) |
| Dyslipidemia | 42 (42%) |
| Diabetes | 29 (29%) |
| Family h/o CAD/CV death | 26 (26%) |
| Serum hs-CRP levels (mean± SD, range) (mg/L) | 4.18±3.30 (0.11-16.3) |

4. **Serum hs-CRP Level**
In our study, majority of the patients were having serum hs-CRP level >3mg/l putting them in high risk category. Of 100 patients, 60 patients (60%) had serum hs-CRP level > 3mg/l, 33 patients (33%) were having serum hs-CRP level 1-3mg/l, while only 7 patients (7%) had serum hs-CRP level < 1 (Fig. 1). The mean value of the serum hs-CRP levels in our study were 4.18±3.30 mg/L. In patients with unstable angina serum hs-CRP was 2.43±1.67 mg/l, with NSTEMI it was 3.70±2.09 mg/l and with STEMI it was highest 5.41±3.83 mg/l, (Table No.2) (Fig.2).
Table No. 2 Levels of serum hS-CRP and Type of Presentation

| Serum hs-CRP level (mg/l) | UA   | NSTEMI | STEMI |
|--------------------------|------|--------|-------|
| <1 mg/l                  | 5    | 1      | 1     |
| 1-3 mg/l                 | 12   | 5      | 13    |
| >3 mg/l                  | 15   | 10     | 38    |
| Total                    | 32   | 16     | 52    |
| Mean serum hs-CRP levels | 2.43±1.67 | 3.70±2.09 | 5.41±3.83 |

Serum hs-CRP Level in Different Subgroups

The mean serum hs-CRP in different risk subgroups (Table No. 3) was similar in patients with and without many of the study risk factors/profiles (gender; p=0.300, and hypertension; p=0.396), while it was significantly higher in those with hyperlipidaemia (p=0.000), With diabetes (p=0.021) with a family history of CAD/CV death (p=0.017), history of smoking (p=0.001), than in those without.
Table No. 3 Serum hs-CRP level in different risk factors subgroups*

| Characteristic                     | Sr. hS-CRP       |
|------------------------------------|------------------|
| Male                               | 4.39±3.20        |
| Female                             | 3.51±3.62        |
| *P value                           | 0.300            |
| With diabetes                      | 5.65±4.30        |
| Without diabetes                   | 3.59±2.61        |
| *P value                           | 0.021            |
| With systemic hypertension         | 3.89±2.99        |
| Without systemic hypertension      | 4.45±3.57        |
| *P value                           | 0.396            |
| With dyslipidemia                  | 5.91±3.95        |
| Without dyslipidemia               | 2.94±1.99        |
| *P value                           | 0.000            |
| With a family history of CAD/CVdeath | 5.75±4.07      |
| Without a family history of CAD/CVdeath | 3.61±2.79     |
| *P value                           | 0.017            |
| With history of smoking            | 4.83±3.54        |
| Without history of smoking         | 2.76±2.14        |
| *P value                           | 0.001            |

*Data are presented as mean ± standard deviation; data were analyzed by t tests

Discussion

Serum hs-CRP Level

In our study we showed, the mean value of the serum hs-CRP levels in Indian subjects were 4.18±3.30 mg/L, which is higher to those reported in other ethnic groups,\(^3\)-\(^4\) and is much higher than that reported in Japanese subjects,\(^5\) consistent with studies to suggest that the concentration of serum hs-CRP is high in Indians.\(^6\)-\(^10\)

In our study, majority of the patients were having serum hs-CRP level >3 mg/l putting them in high risk category, increased serum hs-CRP serum level in patients with acute coronary syndrome support to a role of serum hs-CRP in plaque vulnerability, which is consistent with another study done by Esplugoreal R \textit{et al}, showed that, serum hs-CRP was significantly higher in patients with acute coronary syndrome compared to chronic stable angina \(p=0.004\) and correlate with complex angiographic lesion \(p=0.001\).\(^11\)

Serum hs-CRP Level in Different Subgroups

With serum hs-CRP gaining importance as a marker for future cardiovascular events, interest has developed in patient characteristics as well as lifestyle factors associated with reduced or elevated systemic inflammatory activity.

There are a variety of factors that can influence the concentration of serum hs-CRP. Elevated blood pressure, obesity, smoking, diabetes mellitus, metabolic syndrome, dyslipidaemia and hormone use are the individual characteristics that can increase level of serum hs-CRP along with chronic infection of inflammation. Moderate alcohol consumption, improved fitness, weight loss and medications like statins, fibrates, niacin, aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs) can decrease the level of hsCRP.\(^12\) Extraneous factors that can influence the concentration are seasonal variation, diurnal influence, age, gender and ethnic differences.

In our study, mean serum hs-CRP in different risk subgroups was significantly higher in those with dyslipidaemia \(p=0.000\), With diabetes \(p=0.021\) with a family history of CAD/CV death \(p=0.017\), and with history of smoking \(p=0.001\), which is consistent with other studies, while it was similar in patients with and without many of the study risk factors/profiles (gender; \(p=0.300\), and hypertension; \(p=0.396\)).

Our study cannot prove significant association that history of hypertension is related to the mean serum hs-CRP level, although hypertension was identified as an important risk factor that can increase level of serum hs-CRP.\(^12\) The non-significant association might be attributable to the relatively unawareness...
of patients to therefore a self-reported history of hypertension can underestimate the diagnosis of hypertension, as found in a recent hypertension survey also\textsuperscript{13} and this study was conducted after an ACS, a fact that might have contributed to lower blood pressure than in stable clinical conditions before the ACS.

Regarding sex, men tend to have lower CRP concentrations, (Frohlich et al.,\textsuperscript{14} Geffken et al.,\textsuperscript{15} Hutchinson et al.,\textsuperscript{16} Imhof et al.,\textsuperscript{17}) however some authors report no difference of the CRP concentration by gender (Garcia-Lorda et al.,\textsuperscript{18}). In our study, there was no difference of the CRP concentration by gender (p=0.300)

Limitations of our study
Although the results of this study support the hypothesis, there are some facts to be considered which might affect the results:

- Number of study population was limited.
- Moreover, other putative factors that could affect the serum hs-CRP (e.g. nutritional status and physical activity) were not included in the regression analyses.
- This study was conducted after an ACS, a fact that might have contributed to lower lipid levels and blood pressure than in stable clinical conditions before the ACS. In addition, at this time, high fasting glucose levels could be related to stress-induced

References
1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-72.
2. Third universal definition of myocardial infarction European Heart Journal (2012) 33, 2551–2567.
3. Zebrack JS, Muhlestein JB, Home BD, Anderson JL. Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk insubjects with angina. J Am Coll Cardiol 2002;39:632-637.
4. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999;19:2355-2363.
5. Taniguchi H, Momiyama Y, Ohmori R, Yonemura A, Yamashita T, Tamai S, et al. Association of plasma C-reactive protein levels with presence and extent of coronary stenosis in patients with stable coronary artery disease. Atherosclerosis 2005;178:173-177.
6. Chandalia M, Cabo-Chan AV Jr, Devaraj S, JialalII, Grundy SM, Abate N. Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab 2003;88:3773-6.
7. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001;104:145-50.
8. Dalan R, Jong M, Chan SP, Hawkins R, Choo R, Lim B, et al. High-sensitivity C-reactive protein concentrations among patients with and without diabetes in a multiethnic population of Singapore: CREDENCE Study. Diabetes Metab Syndr Obes 2010;3:187-95.
9. Indulekha K, Surendar J, Mohan V. High sensitivity C-reactive protein, tumor necrosis factor-?, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105). J Diabetes Sci Techno 2011;5:982-8.
10. Deepa R, Velmurugan K, Arvind K, Sivaram P, Sientay C, Uday S, et al. Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in
relation to insulin resistance and glucose intolerance--the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 2006;55:1232-8.
11. Espliguero RA, Avanzas P, Sales JC, Aldama G, Pizzi C, Kaski JC. Reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004;24:401-8.

12. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
13. Espliguero RA, Avanzas P, Sales JC, Aldama G, Pizzi C, Kaski JC. Reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004;24:401-8.

14. Moreira GC, Cipullo JP, Martin JF, Ciorlia LA, Godoy MR, Cesarino CB, et al. Evaluation of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study. J Hypertens 2009;27:1900-1907
15. Frohlich, M, Sund, M, Lowel, H, Imhof, A, Hoffmeister, A, and Koenig, W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J. 2003;24:1365-1372.
16. Geffken, DF, Cushman, M, Burke, GL, Polak, JF, Sakkinen, PA, and Tracy, RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol.

2001;153:242-250.
17. Hutchinson, WL, Koenig, W, Frohlich, M, Sund, M, Lowel, GD, and Pepys, MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem. 2000;46:934-938.
18. Imhof, A, Woodward, M, Doering, A, Helbecque, N, Loewel, H, Amouyel, P, Lowel, GDO, and Koenig, W. Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: Results from three MONICA samples (Augsburg, Glasgow, Lille). European Heart Journal. 2004;25:2092-2100.